Drug Profile
AZD 9496
Alternative Names: AZD-9496Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Acrylates; Antineoplastics; Indoles; Pyridones; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 11 Feb 2021 Discontinued - Phase-I for Breast cancer (Late-stage disease) in United Kingdom, South Korea and USA (PO) (AstraZeneca's pipeline, February 2021)
- 11 Feb 2021 Discontinued - Phase-I for Breast cancer (Newly diagnosed) in Germany and United Kingdom (PO) (AstraZeneca's pipeline, February 2021)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Breast-cancer(Newly diagnosed) in Germany (PO)